B etween 1970 and 2010, the number of cardiovascular deaths per 100 000 persons in the United States has fallen from ≈450 to ≈125, a reduction >70%. 1 This marked decline in cardiovascular mortality represents one of the true success stories of modern medicine. The improving lifespan of both men and women can be attributed principally to prevention of death first from coronary artery disease (CAD) and second from stroke, with a much smaller contribution from other disease states. 2 The decrease in coronary heart disease deaths may be ascribed to both treatment of acute coronary syndromes (ACS) and chronic CAD as well as risk-factor modification. 3 Nonetheless, we remain in the midst of a coronary epidemic, with >2200 deaths per day in the United States because of cardiovascular disease (≈1 death every 39 seconds). 4 
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Coronary plaque thrombosis is found in most patients dying of cardiovascular death. 5 Those plaques which are at high risk for imminent thrombosis (whether the risk period is days, weeks, or months) are termed "vulnerable plaques". 6 Although atherosclerosis is a pan-vascular process arising from systemic inflammation, 7 vulnerable plaques are not present diffusely but are limited in number 8 and are most commonly located in the proximal and midsegments of the epicardial coronary vessels (and distal in the right coronary artery). 9 Although several plaque types have been identified which are prone to thrombosis, pathological studies have found that the majority of such plaques are thin cap fibroatheromas (TCFAs), characterized by a large necrotic core with a thin (<65 µm) fibrous cap consisting of mostly type 1 collagen with few smooth muscle cells, infiltrated with macrophages and T lymphocytes. 9,10 Cellular production of matrix metalloproteinases and other digestive enzymes, exacerbated by high shear and focal cap calcification, results in plaque rupture, leading to tissue factor release and superimposed thrombus formation. Conversely, pathological intimal thickening, fibrotic, and fibrocalcific plaques are less commonly found at the site of coronary thrombosis. A necrotic core-containing fibroatheroma with a thick fibrous cap is believed to be intermediate in risk. 10 Over the past 2 decades, this knowledge has prompted widespread efforts to identify in vivo the structural/morphological, chemical, and physical properties of the TCFA, with the goal of ultimately developing therapies to prevent acute myocardial infarction and sudden cardiac death.
Whereas numerous candidate noninvasive testing modalities have been proposed (the farthest along being multidetector computerized tomography), 11 greater signal-to-noise ratio may be achieved by placing an intravascular imaging device adjacent to an atheroma. Numerous such catheters have been evaluated in humans, with most failing for a variety of device-specific, practical or commercial reasons, including thermography, intravascular magnetic resonance imaging, palpography, angioscopy, and vasa vasorum imaging. However, 3 such devices have emerged and have received Food and Drug Administration approval with "tool" claims that are theoretically capable of identifying certain characteristics of a TCFA: radiofrequency intravascular ultrasound (RF-IVUS), optical coherence tomography (OCT), and near-infrared spectroscopy (NIRS). Unlike gray-scale IVUS, which analyzes only the amplitude of the back-scattered sound waveform, RF-IVUS incorporates frequency domain information, providing greater diagnostic accuracy. 12 OCT is similar to IVUS but uses light as a probe rather than sound, affording substantially greater axial resolution (10-20 µm rather than 150-200 µm), although sacrificing depth of penetration. 13 NIRS analyzes the underlying chemical signature of the atheroma and has been tuned to identify "lipid core plaque" or necrotic core. 14 Unlike RF-IVUS and OCT, NIRS does not create a tomographic image of the lesion but rather displays a "chemogram" of the vessel wall according to a weighted composite spectroscopic signature from the intima to adventitia. All 3 devices create interesting cross-sectional, longitudinal, and sagittal images purporting to represent high-risk human coronary atheroma. So how should these imaging tools be validated as potential detectors of vulnerable plaque?
For decisive confidence that the image created by a noninvasive or invasive modality truly represents vulnerable plaque, a 4-step process is required. First, human autopsy coronary mapping studies should be performed to ensure that the device is able to identify specific tissue components of atherosclerotic plaque with reasonable accuracy, first on a pixel-by-pixel basis and then on a lesion level (plaque phenotype recognition). Second, most plaques responsible for ACS should be shown at the time of the event to have the imaging characteristics consistent with a pathological ruptured TCFA (with thrombus), whereas most plaques responsible for stable CAD syndromes should lack these features. A complementary approach is to demonstrate that a higher proportion of nonculprit lesions (NCLs) in patients with ACS compared with stable CAD are fibroatheromas, which has been demonstrated pathologically. Third, prospective natural history studies must be performed in which NCLs are classified by imaging as either high risk (vulnerable) or not and followed longitudinally to determine whether such imaging representations do indeed identify lesions prone to future rapid lesion progression, rupture, thrombosis, and major adverse cardiac events (MACE). Finally, and most ambitiously, ≥1 systemic or focal/regional therapies for the alleged vulnerable plaques as identified by the imaging tool should be shown to prevent future MACE, as tested in prospective, randomized trials.
RF-IVUS, OCT, and NIRS have been demonstrated, in vitro, to be capable of identifying plaque components compared with histology, and are reasonably accurate for plaque phenotype characterization. [12] [13] [14] Evidence has been presented that each modality identifies its version of vulnerable plaque as being present in the majority of patients with ACS. 12, 13, 15 To date, only RF-IVUS has been demonstrated in prospective natural history studies to be capable of identifying lesions responsible for future MACE. 16, 17 No trials have been initiated to determine whether treating "at-risk" plaques improves long-term lesion-specific or patient outcomes.
In this issue of Circulation: Cardiovascular Imaging, Kato et al 18 provide important new insights regarding the morphology of NCLs in patients with ACS versus stable CAD. From a prospective, multicenter registry in which 3-vessel OCT imaging was performed, with the images analyzed at a blinded core laboratory, the authors convincingly demonstrate that compared with NCLs in patients with stable CAD, NCLs in ACS patients have a wider lipid arc with longer lipid length and with thinner fibrous caps. NCL TCFAs were more frequently identified in patients with ACS than non-ACS, as were undiagnosed plaque ruptures with thrombus. These data thus complement reports from prior studies with RF-IVUS and NIRS. 12, 15 Furthermore, the present study provides novel insights, demonstrating that NCLs in ACS patients more frequently have macrophages present and microchannels adjacent to the lumen. Although the specificity of OCT for macrophage detection may be questioned and the implications of microchannel lumen proximity are unknown (especially as the presence of microchannels was not statistically different between the 2 groups), the company that these measures keep (extensive lipid with thin fibrous caps) adds credence to their potential involvement in the vulnerable plaque process.
Although the authors acknowledge important limitations of their study (including selection bias, relatively few ACS patients, nonquantitative evaluation of several key components and missing data from the most proximal segments of the coronary tree, where TCFAs are pathologically known to reside), 9 2 other issues should be addressed. First, the major drawback of OCT is its limited penetration depth and inability to assess plaque volume. 13, 19 The authors minimize this limitation by stating that "the most important morphological determinants of plaque vulnerability are superficial." This may not be true; in the study, Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT), the strongest independent determinate of future MACE was plaque burden 16 ; the same finding was subsequently reported by the VH-IVUS in Vulnerable Atherosclerosis (VIVA) investigators. 17 Similarly, "lipid volume index" by OCT was defined as the averaged lipid arc multiplied by lipid length-this is at best a poor surrogate for a true volume measure and should be renamed. Second, an important imbalance not emphasized was the higher use of statins in the stable CAD group, which has been demonstrated to increase fibrous cap thickness and decrease atheroma and lipid volume. 20, 21 The present analysis would benefit by multivariable correction of these and other baseline imbalances.
These comments notwithstanding, the authors should be congratulated for a carefully performed study that moves the field forward. However, numerous questions remain to be answered. Which lesion-based OCT characteristics from the present study (if any) are most strongly predictive of future MACE originating from that lesion? Lipid arc or length? Fibrous cap thickness? Macrophage density or microchannel parameters? A prospective natural history study is required to sort this out. What is the temporal stability of OCT-assessed vulnerable plaque parameters? RF-IVUS plaque composition and phenotype have been reported to evolve over a period of months (either to a more stable or unstable morphology). 22 Can the findings from an OCT core laboratory be translated into the catheterization laboratory? In this regard, lipid versus calcium versus signal drop-out may be mischaracterized by nonexpert (and some expert) readers. Lack of blood clearance can be misconstrued as thrombus. Automated or semiautomated edge detection and pattern recognition software would be of great use. Are OCT parameters as or more predictive of plaque vulnerability than either RF-IVUS or NIRS parameters? Concordance between these different imaging modalities in assessing plaque characteristics and phenotype is far from perfect. 23, 24 Multiple modalities may provide synergistic information-for example, combining plaque burden data from IVUS with either fibrous cap thickness from OCT or lipid core plaque content from NIRS.
Most importantly, randomized trials must ultimately be undertaken in patients with high-risk plaques (identified by the imaging tool) to evaluate the use of either new more potent systemic therapies (perhaps representing a future role for proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors, 25 because most patients with coronary atherosclerosis are already prescribed high-dose statins) or focal/regional interventional therapies (eg current drug-eluting stents, emerging bioabsorbable vascular scaffolds, or photodynamic therapy) 26, 27 to demonstrate that treating vulnerable plaques before rupture is effective in preempting future ACS, myocardial infarction, and cardiac death. If such data are absent, 3-vessel invasive screening as performed in PROSPECT and the current study cannot be recommended outside the research setting, given the small but inherent risks of the procedure (coronary dissection and extra contrast and radiation exposure). These considerations notwithstanding, the potential for further reducing the global burden from cardiovascular disease justifies the tremendous efforts being expended in the search for vulnerable plaque.
